136 related articles for article (PubMed ID: 32336490)
1. Intralesional Rituximab Injection for Low-Grade Conjunctival Lymphoma Management.
Demirci H; Ozgonul C; Diniz Grisolia AB; Elner VM
Ophthalmology; 2020 Sep; 127(9):1270-1273. PubMed ID: 32336490
[No Abstract] [Full Text] [Related]
2. Conjunctival and orbital lymphoma.
Shinder R
Ophthalmology; 2011 Aug; 118(8):1692; author reply 1692, 1692.e1. PubMed ID: 21813098
[No Abstract] [Full Text] [Related]
3. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
[TBL] [Abstract][Full Text] [Related]
4. Intralesional rituximab in primary conjunctival follicular lymphoma relapsed.
Rodríguez Villa S; Ruiz Rodríguez MJ; Vargas Pabón M
Arch Soc Esp Oftalmol; 2017 Jul; 92(7):326-329. PubMed ID: 27986437
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Chen R; Frankel P; Popplewell L; Siddiqi T; Ruel N; Rotter A; Thomas SH; Mott M; Nathwani N; Htut M; Nademanee A; Forman SJ; Kirschbaum M
Haematologica; 2015 Mar; 100(3):357-62. PubMed ID: 25596263
[TBL] [Abstract][Full Text] [Related]
6. Treatment of conjunctival mucosa-associated lymphoid tissue lymphoma with intralesional injection of interferon alfa-2b.
Lachapelle KR; Rathee R; Kratky V; Dexter DF
Arch Ophthalmol; 2000 Feb; 118(2):284-5. PubMed ID: 10676800
[No Abstract] [Full Text] [Related]
7. Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial.
Poddubnaya IV; Alekseev SM; Kaplanov KD; Lukavetskyy LM; Rekhtman GB; Dolai TK; Attili VSS; Bermúdez CD; Isaev AA; Chernyaeva EV; Ivanov RA
Hematol Oncol; 2020 Feb; 38(1):67-73. PubMed ID: 31724191
[TBL] [Abstract][Full Text] [Related]
8. A Case Report of Conjunctival Extranodal Marginal Zone Lymphoma Treated with Intralesional Rituximab Injection Therapy.
Yazicioglu T; Oklar M; Kocabas S; Karadag E; Elibol V; Tezcan ME
Ocul Immunol Inflamm; 2022 Aug; 30(6):1329-1333. PubMed ID: 36084297
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
10. Conjunctival extranodal marginal zone B-cell lymphoma with crystal-storing histiocytosis.
Mittal R; Damato B; Coupland SE
Acta Ophthalmol; 2015 Nov; 93(7):e602-3. PubMed ID: 25988528
[No Abstract] [Full Text] [Related]
11. A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan.
Pei SN; Wang MC; Ma MC; Kuo CY; Liao CK; Qiu H; Rothwell LA; Liu Y
Sci Rep; 2021 May; 11(1):10069. PubMed ID: 33980914
[TBL] [Abstract][Full Text] [Related]
12. Favourable response to rituximab by an ocular adnexal primary lymphoma.
Luque Valentin-Fernandez ML; Alvarez Rodríguez F; Rodríguez Jiménez I
Arch Soc Esp Oftalmol; 2016 Nov; 91(11):539-542. PubMed ID: 27125186
[TBL] [Abstract][Full Text] [Related]
13. Intra-lesional interferon injection for recurrent conjunctival MALT lymphoma.
Zayed M; Sears K; Salvi SM; Rundle PA; Rennie IG; Mudhar HS
Eye (Lond); 2013 May; 27(5):680-2. PubMed ID: 23558211
[No Abstract] [Full Text] [Related]
14. Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma.
Sanchez-Gonzalez B; Gimeno E; Garcia-Pallarols F; Ancochea A; Salar A
Leuk Lymphoma; 2014 Oct; 55(10):2384-6. PubMed ID: 24601815
[No Abstract] [Full Text] [Related]
15. Bilateral conjunctival follicular lymphoma in a child.
Wall PB; Traboulsi EI; Hsi ED; Singh AD
J AAPOS; 2015 Apr; 19(2):183-5. PubMed ID: 25824110
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
17. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.
Kalpadakis C; Pangalis GA; Sachanas S; Tsirkinidis P; Kontopidou FN; Moschogiannis M; Yiakoumis X; Koulieris E; Dimopoulou MN; Kokkoris SI; Kyrtsonis MC; Siakantaris MP; Tsourouflis G; Korkolopoulou P; Rontogianni D; Tsaftaridis P; Plata E; Papadaki HA; Panagiotidis P; Angelopoulou MK; Vassilakopoulos TP
Blood; 2018 Aug; 132(6):666-670. PubMed ID: 29914978
[No Abstract] [Full Text] [Related]
18. An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Andorsky DJ; Kolibaba KS; Assouline S; Forero-Torres A; Jones V; Klein LM; Patel-Donnelly D; Smith M; Ye W; Shi W; Yasenchak CA; Sharman JP
Br J Haematol; 2019 Jan; 184(2):215-222. PubMed ID: 30183069
[TBL] [Abstract][Full Text] [Related]
19. Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience.
Tuncer S; Tanyıldız B; Basaran M; Buyukbabani N; Dogan O
Curr Eye Res; 2015; 40(8):780-5. PubMed ID: 25247376
[TBL] [Abstract][Full Text] [Related]
20. Intralesional interferon-α for the treatment of bilateral conjunctival mucosa-associated lymphoid tissue lymphoma.
Holds J; Buchanan A; Hanson R
Pediatr Blood Cancer; 2012 Jul; 59(1):176-8. PubMed ID: 21793177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
